Risk of community-acquired pneumonia in chronic obstructive pulmonary disease stratified by smoking status: A population-based cohort study in the United Kingdom

International Journal of COPD

Volumn 12, Issue , 2017, Pages 2425-2432

  Braeken, Dionne C W ^a,c   Rohde, Gernot G U ^b   Franssen, Frits M E ^a,b   Driessen, Johanna H M ^b,c,d   van Staa, Tjeerd P ^c,e   Souverein, Patrick C ^c   Wouters, Emiel F M ^a,b   de Vries, Frank ^b,c,f  

^a Department of Research and Education   (Austria)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

COPD; Incidence; Respiratory infections; Smoking risk

Indexed keywords

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRIMARY MEDICAL CARE; PROPORTIONAL HAZARDS MODEL; SMOKING; UNITED KINGDOM; COMMUNITY ACQUIRED INFECTION; INCIDENCE; LUNG; MIDDLE AGED; PATHOPHYSIOLOGY; PNEUMONIA; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR;

AGED; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; INCIDENCE; LUNG; MALE; MIDDLE AGED; PNEUMONIA; PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK ASSESSMENT; RISK FACTORS; SMOKING; TIME FACTORS; UNITED KINGDOM;

EID: 85027868655     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S138435     Document Type: Article

References (53)

1. Herrero FS, Olivas JB. Microbiology and Risk Factors for Community-acquired Pneumonia. Semin Respir Crit Care Med. 2012;33(3): 220–231.
2. Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Blanco T, Raga-Luria X, Gomez-Bertomeu F; Group ES. Epidemiology of community-acquired pneumonia in older adults: a population-based study. Respir Med. 2009;103(2):309–316.
3. Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009;64(Suppl 3):iii1–iii55.
4. Torres A, Peetermans WE, Viegi G, Blasi F. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax. 2013;68(11):1057–1065.
5. Müllerova H, Chigbo C, Hagan GW, et al. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med. 2012;106(8):1124–1133.
6. Braeken DCW, Franssen FME, Schuette H, et al. Increased severity and mortality of CAP in COPD: results from the German Competence Network, CAPNETZ. Chronic Obstr Pulm Dis. 2015;2(2): 131–140.
7. Molinos L, Clemente MG, Miranda B, et al; ASTURPAR Group. Community-acquired pneumonia in patients with and without chronic obstructive pulmonary disease. J Infect. 2009;58(6):417–424.
8. Bagaitkar J, Demuth DR, Scott DA. Tobacco use increases susceptibility to bacterial infection. Tob Induc Dis. 2008;4:12.
9. Bauer CM, Morissette MC, Stampfli MR. The influence of cigarette smoking on viral infections: translating bench science to impact COPD pathogenesis and acute exacerbations of COPD clinically. Chest. 2013;143(1):196–206.
10. van Eerd EAM, van Rossem CR, Spigt MG, Wesseling G, van Schayck OCP, Kotz D. Do we need tailored smoking cessation interventions for smokers with COPD? A comparative study of smokers with and without COPD regarding factors associated with tobacco smoking. Respiration. 2015;90(3):211–219.
11. Getsios D, Marton JP, Revankar N, et al. Smoking cessation treatment and outcomes patterns simulation: a new framework for evaluating the potential health and economic impact of smoking cessation interventions. Pharmacoeconomics. 2013;31(9):767–780.
12. Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol. 2015; 44(3):827–836.
13. Roland M. Linking physicians’ pay to the quality of care – a major experiment in the United kingdom. N Engl J Med. 2004;351(14): 1448–1454.
14. Wvan der Zanden R, de Vries F, Lalmohamed A, et al. Use of dipeptidyl-peptidase-4 inhibitors and the risk of pneumonia: a population-based cohort study. PLoS One. 2015;10(10):e0139367.
15. Millett ER, De Stavola BL, Quint JK, Smeeth L, Thomas SL. Risk factors for hospital admission in the 28 days following a community-acquired pneumonia diagnosis in older adults, and their contribution to increasing hospitalisation rates over time: a cohort study. BMJ Open. 2015; 5(12):e008737.
16. Mullerova H, Shukla A, Hawkins A, Quint J. Risk factors for acute exacerbations of COPD in a primary care population: a retrospective observational cohort study. BMJ Open. 2014;4(12):e006171.
17. Garcia Rodriguez LA, Wallander MA, Tolosa LB, Johansson S. Chronic obstructive pulmonary disease in UK primary care: incidence and risk factors. COPD. 2009;6(5):369–379.
18. de Vries F, Setakis E, Zhang B, van Staa TP. Long-acting {beta}2-agonists in adult asthma and the pattern of risk of death and severe asthma outcomes: a study using the GPRD. Eur Respir J. 2010;36(3): 494–502.
19. Zhang B, de Vries F, Setakis E, van Staa TP. The pattern of risk of myocardial infarction in patients taking asthma medication: a study with the general practice research database. J Hypertens. 2009;27(7): 1485–1492.
20. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the general practice research database: a systematic review. Br J Clin Pharmacol. 2010;69(1):4–14.
21. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of Chronic Obstructive Pulmonary Disease. 2015; Available from: http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html. Accessed February 17, 2015.
22. Booth HP, Prevost AT, Gulliford MC. Validity of smoking prevalence estimates from primary care electronic health records compared with national population survey data for England, 2007 to 2011. Pharmacoepidemiol Drug Saf. 2013;22(12):1357–1361.
23. de Vries F, van Staa TP, Bracke MS, Cooper C, Leufkens HG, Lammers JW. Severity of obstructive airway disease and risk of osteo-porotic fracture. Eur Respir J. 2005;25(5):879–884.
24. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ. 2003;326(7382):219.
25. Ryan M, Suaya JA, Chapman JD, Stason WB, Shepard DS, Thomas CP. Incidence and cost of pneumonia in older adults with COPD in the United States. PLoS One. 2013;8(10):e75887.
26. DiSantostefano RL, Sampson T, Le HV, Hinds D, Davis KJ, Bakerly ND. Risk of pneumonia with inhaled corticosteroid versus long-acting bronchodilator regimens in chronic obstructive pulmonary disease: a new-user cohort study. PLoS One. 2014;9(5):e97149.
27. Capelastegui A, Espana PP, Bilbao A, et al. Study of community-acquired pneumonia: incidence, patterns of care, and outcomes in primary and hospital care. J Infect. 2010;61(5):364–371.
28. Thomsen RW, Riis A, Norgaard M, et al. Rising incidence and persistently high mortality of hospitalized pneumonia: a 10-year population-based study in Denmark. J Intern Med. 2006;259(4):410–417.
29. Millett ER, Quint JK, Smeeth L, Daniel RM, Thomas SL. Incidence of community-acquired lower respiratory tract infections and pneumonia among older adults in the United Kingdom: a population-based study. PLoS One. 2013;8(9):e75131.
30. Gutierrez F, Masia M, Mirete C, et al. The influence of age and gender on the population-based incidence of community-acquired pneumonia caused by different microbial pathogens. J Infect. 2006;53(3): 166–174.
31. Mannino DM, Davis KJ, Kiri VA. Chronic obstructive pulmonary disease and hospitalizations for pneumonia in a US cohort. Respir Med. 2009;103(2):224–229.
32. Raho E, van Oostrom SH, Visser M, et al. Generation shifts in smoking over 20 years in two Dutch population-based cohorts aged 20–100 years. BMC Public Health. 2015;15:142.
33. Bilal U, Beltran P, Fernandez E, Navas-Acien A, Bolumar F, Franco M. Gender equality and smoking: a theory-driven approach to smoking gender differences in Spain. Tob Control. 2016;25(3):295–300.
34. Lamprecht B, Vanfleteren LE, Studnicka M, et al. Sex-related differences in respiratory symptoms: results from the BOLD Study. Eur Respir J. 2013;42(3):858–860.
35. Marrie TJ, Huang JQ. Low-risk patients admitted with community-acquired pneumonia. Am J Med. 2005;118(12):1357–1363.
36. Aliyu ZY, Aliyu MH, McCormick K. Determinants for hospitalization in “low-risk” community acquired pneumonia. BMC Infect Dis. 2003;3:11.
37. Almirall J, Bolibar I, Serra-Prat M, et al. New evidence of risk factors for community-acquired pneumonia: a population-based study. Eur Respir J. 2008;31(6):1274–1284.
38. Almirall J, Gonzalez CA, Balanzo X, Bolibar I. Proportion of community-acquired pneumonia cases attributable to tobacco smoking. Chest. 1999;116(2):375–379.
39. Baik I, Curhan GC, Rimm EB, Bendich A, Willett WC, Fawzi WW. A prospective study of age and lifestyle factors in relation to community-acquired pneumonia in US men and women. Arch Intern Med. 2000;160(20):3082–3088.
40. Arcavi L, Benowitz NL. Cigarette smoking and infection. Arch Intern Med. 2004;164(20):2206–2216.
41. Myint PK, Lowe D, Stone RA, Buckingham RJ, Roberts CM. UK National COPD Resources and Outcomes Project 2008: patients with chronic obstructive pulmonary disease exacerbations who present with radiological pneumonia have worse outcome compared to those with non-pneumonic chronic obstructive pulmonary disease exacerbations. Respiration. 2011;82(4):320–327.
42. Pan Z, Yu H, Liao JL. Probing cellular and molecular mechanisms of cigarette smoke-induced immune response in the progression of chronic obstructive pulmonary disease using multiscale network modeling. PLoS One. 2016;11(9):e0163192.
43. Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in nonsmokers. Lancet. 2009;374(9691):733–743.
44. Carraro S, Scheltema N, Bont L, Baraldi E. Early-life origins of chronic respiratory diseases: understanding and promoting healthy ageing. Eur Respir J. 2014;44(6):1682–1696.
45. Almirall J, Blanquer J, Bello S. Community-acquired pneumonia among smokers. Arch Bronconeumol. 2014;50(6):250–254.
46. Crim C, Calverley PM, Anderson JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Res J. 2009;34(3):641–647.
47. Clinical Practice Research Datalink. Available from: http://www.cprd.com. Accessed January 20, 2016.
48. Rothman KJ, Greenland S, Lash TL. Modern Epidemiology. Lippincott Williams and Wilkins; Philadelphia: Lippincott Williams & Wilkins; 2008:137–144.
49. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27–S72.
50. Finney L, Berry M, Singanayagam A, Elkin SL, Johnston SL, Mallia P. Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease. Lancet Respir Med. 2014;2(11):919–932.
51. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012;67(1):71–79.
52. Grau I, Ardanuy C, Calatayud L, Schulze MH, Linares J, Pallares R. Smoking and alcohol abuse are the most preventable risk factors for invasive pneumonia and other pneumococcal infections. Int J Infect Dis. 2014;25:59–64.
53. Cecere LM, Williams EC, Sun H, et al. Smoking cessation and the risk of hospitalization for pneumonia. Respir Med. 2012;106(7):1055–1062.